ClinicalTrials.gg
Status unknownNCT05418829Updated Jun 14, 2022

AT-007 in Adult Subjects With Classic Galactosemia (CG)

A Phase 3 interventional study of AT-007 in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Applied Therapeutics, Inc. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG who previously participated in Study AT-007-1001 Part D and/or Part D Extension.

The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects with CG will also be evaluated.

Read the detailed description

Primary:

  • To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with Classic Galactosemia (CG)

Secondary:

  • To evaluate the long-term inhibition of galactitol, a biomarker of aldose reductase (AR) activity, induced by 12-month oral administration of AT-007 to adult subjects with CG
  • To evaluate the pharmacokinetic (PK) parameters of 12-month oral administration of AT-007 in adult subjects with CG

Exploratory:

  • To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG
  • To evaluate the burden of illness (BOI) of adult subjects with CG
  • To evaluate quality of life (QOL) measures of adult subjects with CG
  • To evaluate the effect of 12-month oral administration of AT-007 on the BOI and QOL of adult subjects with CG
02

Conditions studied

  • Classic Galactosemia
03

In context

Lead sponsor

Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating female subject with a CG diagnosis
  • Previous participation in Study AT-007-1001 Part D and/or Part D Extension
  • No other significant health problems which preclude participation

Exclusion criteria

Exclusion Criteria:

  • Concomitant use of certain medications or over-the-counter therapies
  • Discontinuation from Study AT-007-1001 Part D and/or Part D Extension due an adverse event
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    AT-007

    Open-label AT-007 20 mg/kg once daily

    Drug: AT-007

Interventions

  • DrugAT-007

    AT-007 20 mg/kg once daily

06

What researchers measure

Primary outcomes

  1. To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by adverse events.

    Number of participants with treatment-emergent adverse events and broken down by organ class and relatedness.

    Time frame: 12 months

  2. To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by clinical laboratory test results.

    Number of participants with clinically-significant changes in clinical laboratory test results.

    Time frame: 12 months

  3. To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by physical exam parameters.

    Number of participants with clinically-significant changes in physical examination findings, vital sign abnormalities, and electrocardiogram findings.

    Time frame: 12 months

Secondary outcomes

  1. To evaluate the long-term change of galactitol, a biomarker of AR activity, induced by 12-month oral administration of AT-007 to adult subjects with CG

    Time frame: 12 months

  2. To evaluate the pharmacokinetic (PK) parameter maximum concentration (Cmax) of 12-month oral administration of AT-007 in adult subjects with CG

    Maximum concentration will be determined by individual concentration time-data (mg/L)

    Time frame: 12 months

  3. To evaluate the pharmacokinetic (PK) parameter Area-Under-the-Curve (AUC) of 12-month oral administration of AT-007 in adult subjects with CG (mg*h/L)

    Time frame: 12 months

Other outcomes

  1. To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG

    Time frame: 12 months

  2. To evaluate the burden of illness (BOI) of adult subjects with CG- Medical History

    Narrative description of natural course of CG as extracted by chart review and physical exam findings noted in chart review including the baseline neurologic exam upon entering the clinical trial. (There are no units for a descriptive narrative of medical history)

    Time frame: 12 months

  3. To evaluate the burden of illness (BOI) of adult subjects with CG- NIH Motor Battery

    NIH Motor Battery produces normalized percentile scores with higher scores being more normal. As an exploratory endpoint, changes in the score from baseline to month 12 will assessed.

    Time frame: 12 months

  4. To evaluate the burden of illness (BOI) of adult subjects with CG- Spiral Drawing Test

    Spiral Drawing Test produces normalized percentile scores with higher scores being more normal. As an exploratory endpoint, changes in the score from baseline to month 12 will assessed.

    Time frame: 12 months

  5. To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Emotional Distress questionnaire

    The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]

    Time frame: 12 months

  6. To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Emotional Support questionnaire

    The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]

    Time frame: 12 months

  7. To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Companionship questionnaire

    The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]

    Time frame: 12 months

  8. To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Social Isolation questionnaire

    The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]

    Time frame: 12 months

  9. To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Ability to Participate in Social Roles and Activities questionnaire

    The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]

    Time frame: 12 months

07

Study locations

1 site
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Nov 2022, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Jun 14, 2022
StartActual
Oct 1, 2021
Primary completionEst.
Nov 2022
CompletionEst.
Dec 2022
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05418829
Lead sponsor
Applied Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Oct 1, 2021
Primary completion
Nov 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jun 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Govorestat

Start the discussion